Keyphrases
Adverse Events
7%
Anti-tumor Necrosis Factor (anti-TNF)
23%
Clinical Remission
14%
Clostridium Difficile Infection
9%
Colectomy
11%
Colon Resection
15%
Confidence Interval
9%
Corticosteroids
8%
COVID-19
10%
COVID-19 mRNA Vaccine
9%
Crohn's Colitis
7%
Crohn's Disease
58%
Disease Activity
9%
Disease Activity Score
8%
Disease Progression
6%
Drug Sustainability
9%
During Pregnancy
9%
Dysplasia
9%
Fecal Calprotectin
20%
Hazard Ratio
10%
Histologic
6%
Hospitalization
6%
Ileal Pouch-anal Anastomosis
12%
Induction Therapy
6%
Inflammation
13%
Inflammatory Bowel Disease
100%
Infliximab
20%
Israel
11%
Israeli
11%
J-pouch
17%
Lung Transplantation
14%
Mediterranean Diet
9%
Moderate to Severe
13%
Newly Diagnosed
9%
Non-associated
7%
Postoperative Recurrence
9%
Pouch
23%
Pouchitis
20%
Real-world Experience
9%
Response to COVID-19
9%
Retrospective Cohort Study
8%
Risk Factors
6%
Serological Response
11%
Severe Ulcerative Colitis
11%
Tertiary Care Hospital
20%
Tofacitinib
15%
Tumor Necrosis Factor-α
9%
Ulcerative Colitis
40%
Ustekinumab
19%
Vedolizumab
22%
Medicine and Dentistry
Adverse Event
6%
Antibiotic Therapy
5%
Biological Product
8%
Cohort Analysis
9%
Colectomy
18%
Colitis
15%
Colon
5%
Coronavirinae
5%
COVID-19
9%
Crohn's Disease
38%
Cross Sectional Study
6%
Disease Activity
13%
Disease Exacerbation
7%
Diseases
42%
Dysplasia
9%
Faecal Calprotectin
17%
Fistula
10%
Hazard Ratio
10%
Ileo-Anal Pouch
8%
Ileocolonoscopy
5%
Infection
14%
Inflammatory Bowel Disease
59%
Infliximab
24%
Limb
9%
Lung Transplantation
5%
Neoplasm
6%
Patient Referral
9%
Patient with Crohn's Disease
17%
Patient with Inflammatory Bowel Disease
55%
Patient with Ulcerative Colitis
16%
Pediatrics
12%
Pouchitis
26%
Pulmonary Hypertension
5%
Quality of Life
7%
Recurrent Disease
25%
Retrospective Cohort Study
8%
Surgical Anastomosis
19%
Therapeutic Drug Monitoring
5%
TNF Inhibitor
6%
Tumor Necrosis Factor
25%
Ulcerative Colitis
45%
Ustekinumab
11%
Vedolizumab
18%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Biological Product
8%
C Reactive Protein
5%
Calgranulin
7%
Cohort Study
11%
Colitis
10%
Coronavirinae
5%
Crohn's Disease
41%
Cross-Sectional Study
5%
Diseases
24%
Ileitis
5%
Infection
9%
Inflammation
6%
Inflammatory Bowel Disease
53%
Infliximab
19%
Janus Kinase
5%
Recurrent Disease
22%
Remission
18%
Tacrolimus
6%
Therapeutic Drug Monitoring
5%
Tofacitinib
16%
Tumor Necrosis
6%
Tumor Necrosis Factor
30%
Tumor Necrosis Factor Inhibitor
5%
Ulcerative Colitis
33%
Ustekinumab
15%
Vedolizumab
13%
